Results 11 to 20 of about 743,600 (215)
Zolpidem in Progressive Supranuclear Palsy [PDF]
Case Reports in Neurological Medicine, 2013 Progressive supranuclear palsy (PSP) is a progressive neurodegenerative disorder, characterized by motor symptoms, postural instability, personality changes, and cognitive impairment. There is no effective treatment for this disorder.
Sandip K. Dash
doaj +5 more sources
A longitudinal study of motor, oculomotor and cognitive function in progressive supranuclear palsy.
PLoS ONE, 2013 ObjectiveWe studied the annual change in measures of motor, oculomotor and cognitive function in progressive supranuclear palsy. This had twin objectives, to assess the potential for clinical parameters to monitor disease progression in clinical trials ...
Boyd C P Ghosh +2 more
doaj +2 more sources
Clinical Features of Patients With Progressive Supranuclear Palsy in an US Insurance Claims Database
Frontiers in Neurology, 2021 Background: Progressive supranuclear palsy is a rare neurodegenerative movement disorder and little is known about its epidemiology.Objective: Estimate age-adjusted prevalence of progressive supranuclear palsy and describe antecedent diagnoses and ...
Emma Viscidi +11 more
doaj +2 more sources
Genetics of Progressive Supranuclear Palsy [PDF]
Journal of Movement Disorders, 2015 Progressive supranuclear palsy (PSP) is a neurodegenerative syndrome that is clinically characterized by progressive postural instability, supranuclear gaze palsy, parkinsonism and cognitive decline.
Sun Young Im +2 more
doaj +3 more sources
Progressive Supranuclear Palsy
, 2019 Summary: ● Progressive supranuclear palsy (PSP) ○ Progressive disorder of the elderly ○ Supranuclear → doll\u27s head maneuver overcomes the ophthalmoplegia ○ Bilateral, symmetric ● Down-gaze palsy is the key feature of PSP ○ Elderly patients - it often ...
Andrew G. Lee, MD; Jared Alexander
core +5 more sources
Falls in Progressive Supranuclear Palsy. [PDF]
Movement Disorders Clinical Practice, 2019 BACKGROUND: Despite falls being an almost universal clinical feature and central to the presentation and diagnostic criteria of progressive supranuclear palsy, our understanding of falls is surprisingly limited and there are few effective treatment ...
Brown, Fraser S +3 more
core +4 more sources
Análisis de genes situados en el haplotipo H1 de la región 17q21 y de genes involucrados en la fosforilación de "tau" en la parálisis supranuclear progresiva [PDF]
, 2007 [spa] INTRODUCCIÓN: La parálisis supranuclear progresiva (PSP) se caracteriza por el depósito anormal de proteína tau hiperfosforilada en ganglios basales y tronco cerebral.
Campdelacreu i Fumadó, Jaume
core +6 more sources
Progressive supranuclear palsy [PDF]
Seminars in Neurology, 2001 Unfortunately, no drug treatment has been shown to benefit patients with progressive supranuclear palsy (PSP) more than modestly or briefly. The multiplicity of neuronal systems and synaptic physiologies that degenerate in this disorder makes a neurotransmitter-specific approach, such as neurotransmitter replacement or reuptake inhibition, unlikely to ...
K, Tawana, D B, Ramsden
openaire +5 more sources
Progressive Supranuclear Palsy
The Neurologist, 2008 Progressive Supranuclear PalsyIC-E10ci2-progressive-supranuclear ...
Kathleen B. Digre, MD
core +3 more sources
Fluid Intelligence and Executive Dysfunction in Progressive Supranuclear Palsy. [PDF]
Mov Disord Clin PractAbstract Background Fluid intelligence (g) contributes to executive‐task performance, but its role in progressive supranuclear palsy (PSP) remains unclear. Objectives To examine whether executive deficits in PSP are explained by reductions in g. Methods Thirty‐five PSP patients, 39 Parkinson's disease (PD) patients and 18 healthy controls underwent ...
Castano F, Roca M, Duncan J, Couto B.
europepmc +2 more sources